Written questions by Ribeiro-Addy.

What steps he is taking to raise awareness of sickle cell disease amongst the Latin American and Latinx community.

The Government is committed to improving the lives of those living with rare diseases such as sickle cell disease. Increasing awareness of rare diseases in healthcare professionals is one of the four priorities of the UK Rare Diseases Framework. We published the annual England action plan in February 2025, where we report on the steps we have taken to advance this priority.In England, there are approximately 17,000 people living with sickle cell disease, an inherited blood disorder with approximately 250 new cases a year. It is the fastest growing genetic condition in the country. It is generally more common in people of black African and black Caribbean heritage, 77% of patients, however, we recognise that the condition is not unique to this community and NHS England remains committed to delivering quality improvement to all patients living with sickle cell.Our national Can You Tell its Sickle Cell campaign launched in 2022, to boost public awareness of sickle cell disease, including in the Latin American and Latinx community, and help staff better understand the condition, crises, and how to care for patients during their greatest hour of need. Co-developed with NHS England’s patient advisory group, clinical experts, and the Sickle Cell Society, the campaign included staff resources as well as hand-held patient cards distributed via haemoglobinopathy coordinating centres. The campaign was relaunched as part of Sickle Cell Awareness Month in 2025, and an information toolkit remains available on the national Campaign Resource Centre.

What steps his Department is taking to increase diagnosis of sickle cell amongst patients of Latin American descent.

The Government is committed to improving the lives of those living with rare diseases such as sickle cell disease. Helping patients get a final diagnosis faster is one of the four priorities of the UK Rare Diseases Framework. We published the annual England action plan in February 2025, where we report on the steps we have taken to advance this priority.In England, there are around 17,000 people living with sickle cell disease, an inherited blood disorder with around 250 new cases a year. It is the fastest growing genetic condition in the country. It is generally more common in people of Black African and Black Caribbean heritage (77% of patients) however, we recognise that the condition is not unique to this community and NHS England remain committed to delivering quality improvement to all patients living with sickle cell.All pregnant women in England are offered a blood test to find out if they carry a gene for thalassaemia. Those at high risk of being a sickle cell carrier are offered a test for sickle cell. As part of the National Health Service Antenatal Sickle Cell and Thalassaemia (SCT) Screening Programme, the Family Origin Questionnaire (FOQ) is mandatory for all booking blood requests. By recording accurate family origin details, the FOQ enables midwives to identify women at higher risk. For example, women with Latin American ancestry extending back two generations are considered high risk and are offered screening accordingly.

What steps his Department is taking to increase blood donations among Latin American people in (a) Lambeth and (b) the rest of the UK.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England. NHSBT does not plan to add 'Latin American' to blood donation forms at this time. The Office for National Statistics (ONS) includes a list of ethnic groups that should be used when defining an individual’s background, and the term Latin America(n) is not used. Further information on the list of ethnic groups that should be used when defining an individual’s background is available at the following link:https://www.ons.gov.uk/methodology/classificationsandstandards/measuringequality/ethnicgroupnationalidentityandreligionThe heritage of a donor from the Latin American region can be described within mixed white, black, and other groupings. The NHS Digital site also refers to the ONS definitions, and is available at the following link:https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-sets/mental-health-services-data-set/submit-data/data-quality-of-protected-characteristics-and-other-vulnerable-groups/ethnicityNHSBT uses several initiatives to increase blood donations and in turn improve blood stocks, and this includes marketing and communications campaigns. All activity is planned using data and insights about diverse audiences, including those from ethnic minorities. Central to all decision making is the ability to reach and connect with people from ethnic minority backgrounds. NHSBT consults with a specialist media agency to ensure they are using culturally appropriate and audience specific channels to reach mixed heritage and ethnic minority populations.

What assessment he has made of the potential merits of supporting a formal bilateral exchange of medical expertise between Cuba and the United Kingdom to promote health equity.

In our ever more interconnected world, international cooperation is fundamental to driving medical breakthroughs and saving lives. By sharing knowledge, resources, and expertise, international collaborations can overcome limitations faced by individual nations and achieve breakthroughs that benefit patients all over the world.The Government remains steadfast in its commitment to international collaboration on health and highly values the bilateral relationship between the United Kingdom and Cuba. The Government has a longstanding policy of engagement with Cuba, including positive collaboration in areas of mutual interest.

Whether he has made a recent assessment of the potential merits of collaboration between UK and Cuban research institutions on (a) public health and (b) genetic medicine.

In our ever more interconnected world, international research cooperation is fundamental to driving medical breakthroughs and saving lives. By sharing knowledge, resources, and expertise, international collaborations can overcome limitations faced by individual nations and achieve breakthroughs that benefit patients all over the world.Whilst no assessment has been undertaken on the specific merits of research collaboration with Cuba, through the Department funded National Institute for Health and Care Research, the Department works internationally to fund, support, and enable high impact research to address national and global health challenges.

What assessment he has made of the potential merits of international cooperation in healthcare.

In our ever more interconnected world, international cooperation is fundamental to driving medical breakthroughs and saving lives. Health challenges such as pandemics, antimicrobial resistance and climate-related impacts do not respect borders. By sharing knowledge, resources, and expertise, international cooperation can overcome limitations faced by individual nations and achieve breakthroughs that benefit patients all over the world, including the United Kingdom.The Government is committed to collaborating with our international partners and continues to engage with global health institutions, including the World Health Organization. These efforts help build resilient health systems worldwide, reduce preventable deaths and safeguard against shared threats, while supporting UK prosperity through trade and investment in health and life sciences.

Which blood donation centres have begun a trial of the Post Donation Testing for advanced Hb assessments.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England.  NHSBT’s post donation testing feasibility study will assess if an analyser-based blood count, including a haemoglobin (Hb) assessment, can be used to assess a whole blood donor’s ability to have a blood collection taken safely without the need for a Hb measurement at subsequent donation appointments. If the donor’s Hb is above specific thresholds, it will determine the need for testing at their next visit, or for a deferral period based on the Hb being too low to donate. This will start NHSBT’s ability to personalise the deferral period of donors with low Hb.This study started collecting baseline data in the London Middlesex mobile team and will roll out to the Manchester Norfolk House and Nottingham Donor Centres. These teams have been targeted to assess if testing is possible under current mobile and donor centre processes, rather than targeting specific donor groups or demographics.

What assessment his Department has made of the potential impact of the enhanced pre-donation testing process pilot on reducing the number of deferrals for low Hb levels.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England. NHSBT tests donors’ haemoglobin (Hb) to ensure they are at sufficient levels to safely donate.NHSBT has recently changed its testing to include the first line finger prick and blood drop test using copper sulphate that estimates donors’ Hb to be above the threshold for donation. If this test is failed, second line testing with venous HemoCue, a more accurate quantitative test, is carried out. If passed, a donor can donate. If failed, a donor is deferred to ensure they can replenish low iron stores to allow their Hb to improve back to safe donation thresholds.Earlier in 2025, the peak of low Hb deferrals was greater than 12%. With the rollout of venous HemoCue across the country, this has fallen to 4.5% of donors attending per week and has remained below 5% since 15 September 2025, resulting in improved collections.

What demographic data his Department considered when choosing blood donation centres to pilot the post donation testing for advanced Hb assessment.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England.  NHSBT’s post donation testing feasibility study will assess if an analyser-based blood count, including a haemoglobin (Hb) assessment, can be used to assess a whole blood donor’s ability to have a blood collection taken safely without the need for a Hb measurement at subsequent donation appointments. If the donor’s Hb is above specific thresholds, it will determine the need for testing at their next visit, or for a deferral period based on the Hb being too low to donate. This will start NHSBT’s ability to personalise the deferral period of donors with low Hb.This study started collecting baseline data in the London Middlesex mobile team and will roll out to the Manchester Norfolk House and Nottingham Donor Centres. These teams have been targeted to assess if testing is possible under current mobile and donor centre processes, rather than targeting specific donor groups or demographics.

With reference to Breast Cancer Awareness Month, what steps he is taking in November 2025 to promote inclusive (a) wig and (b) prosthetic services.

The Department and the National Health Service in England recognise that there are particular challenges for specific groups of people and for breast cancer care, particularly concerning the promotion of inclusive wigs and prosthetic services.For wigs and accessories, NHS Supply Chain has conducted extensive engagement nationally to fully understand the provision and supply and is working closely with industry groups to support access to the wigs framework, to provide a wider range of products for NHS providers to access. Appropriateness for the wearer has been one of the fundamental focus areas of consideration in this work.Decisions about the funding and provision of health services, including prosthetic services, are the responsibility of local integrated care boards. NHS England funded audits into primary and metastatic breast cancer to help identify and reduce inequalities and variations in care. Using routine data collected on patients diagnosed with breast cancer in an NHS setting, the audits bring together information to look at what is being done well, where it is being done well, and what needs to be done better. Findings were published in September 2025, and the NHS is acting on the findings.

What discussions he has had with NHS England to ensure the procurement of suitable (a) prosthetics and (b) wigs suitable for ethnic minority patients meets diverse patient needs.

The current NHS Supply Chain Wigs Framework Agreement was awarded to 42 suppliers and provides a range of wigs, both real and synthetic, and headwear products to provide alternative choices to patients, as well as maintenance, styling, alteration, and repair services.Whilst there is availability of Afro Caribbean wigs through the currently awarded suppliers, NHS Supply Chain is aware that due to the regionality of suppliers and the nature of them being predominantly micro and small to medium enterprises in many instances, patient choice and access across the United Kingdom can be subject to regional variation.NHS Supply Chain acknowledges that there is a need to develop the framework offering to support an increase in accessibility to patients for Afro Caribbean products and services, and NHS Supply Chain is preparing to introduce enhanced specifications and a specific category for Afro Caribbean for the successor framework agreement due to launch on 1 February 2027.NHS Supply Chain’s new Prosthetics, Components and Associated products Framework Agreement is due to launch on 24 November 2025, to replace the current Artificial Limbs framework. The new framework will offer over 95,000 products delivered by 12 suppliers to provide clinical choice to meet patient need. Ensuring that a patient has a prosthetic limb which blends with their actual skin tone is part of the routine standard of care. NHS Supply Chain works closely with the leading national charities and has not had any issues raised concerning accessing appropriate skin tone.

What assessment he has made of the potential impact of a limited access to suitable (a) prosthetics and (b) wigs on ethnic minority patients; and what steps he is taking to improve access.

The current NHS Supply Chain Wigs Framework Agreement was awarded to 42 suppliers and provides a range of wigs, both real and synthetic, and headwear products to provide alternative choices to patients, as well as maintenance, styling, alteration, and repair services.Whilst there is availability of Afro Caribbean wigs through the currently awarded suppliers, NHS Supply Chain is aware that due to the regionality of suppliers and the nature of them being predominantly micro and small to medium enterprises in many instances, patient choice and access across the United Kingdom can be subject to regional variation.NHS Supply Chain acknowledges that there is a need to develop the framework offering to support an increase in accessibility to patients for Afro Caribbean products and services, and NHS Supply Chain is preparing to introduce enhanced specifications and a specific category for Afro Caribbean for the successor framework agreement due to launch on 1 February 2027.NHS Supply Chain’s new Prosthetics, Components and Associated products Framework Agreement is due to launch on 24 November 2025, to replace the current Artificial Limbs framework. The new framework will offer over 95,000 products delivered by 12 suppliers to provide clinical choice to meet patient need. Ensuring that a patient has a prosthetic limb which blends with their actual skin tone is part of the routine standard of care. NHS Supply Chain works closely with the leading national charities and has not had any issues raised concerning accessing appropriate skin tone.

What steps his Department is taking to ensure that people with female reproductive systems are informed about symptoms of (a) ovarian and (b) other gynaecological cancers through NHS cervical screening programmes.

NHS England works to ensure that core public information on screening is easily accessible and understandable to the public, and it regularly and systematically reviews this information.Earlier this year, NHS England updated its cervical screening guidance to include that cervical screening is not a check for other cancers of the reproductive system, such as ovary, womb, vulval, or vaginal cancer. This guidance is available at the following link:https://www.gov.uk/government/publications/cervical-screening-description-in-brief/cervical-screening-helping-you-decide--2The guidance advises that you should not wait to contact a general practitioner if you have any concerns.

What steps her Department has taken to ensure (a) GPs and (b) mental health professionals are trained in (i) identifying and (ii) responding to the (A) traumatic physical and emotional impacts of violence and abuse and (B) the specific consequences of abuse for Black and minoritised victims.

All National Health Service staff are required to complete mandatory safeguarding training which includes how to identify and respond to domestic abuse and sexual violence. This training is being revised and is due to be re-launched in early 2026. The training update will strengthen the importance of intersectional considerations, including helping staff to understand the impact of trauma and cultural barriers to discussing abuse.General practitioners, along with other clinicians in the NHS, support victims and survivors of abuse in a range of ways depending on diagnosis and individual needs. This may include treating abuse-related injuries, referral to mental health treatment, or referral to a psychological support service such as peer support.All mental health service providers are expected to embed the Patient and carer race equality framework. This mandatory framework supports trusts and providers to implement actions to reduce racial inequalities within their services. It will become part of Care Quality Commission inspections. The Framework is available at the following link:https://www.england.nhs.uk/publication/patient-and-carer-race-equality-framework/Most integrated care boards and NHS trusts have appointed domestic abuse and sexual violence leads. They comprise a national network of leaders who share good practice, identify issues and develop solutions to support victim and survivors, including those from Black and minority groups.

With reference to the Imkaan report entitled Why should our rage be tidy, published in November 2024, what steps his Department is taking to increase the diversity of the NHS therapeutic workforce.

The National Health Service has an incredibly diverse workforce with over 75% of roles filled by women and over 25% of roles filled by people from an ethnic minority background. We expect NHS organisations to work to address inequalities that exist in the workplace to ensure the best outcomes for patients. As part of the Equality, Diversity and Inclusion Improvement Plan, employers across the NHS must embed fair and inclusive recruitment processes and talent management strategies that target under representation and lack of diversity in the workforce. Local NHS leaders remain best placed to take an evidence-based approach to recruitment and resourcing decisions.

Whether his Department plans to (a) bring forward modernised UK-specific legislative proposals for Substances of Human Origin (SoHO) and (b) (i) adopt and (ii) adapt relevant elements of the EU’s updated SoHO legislation.

The Substances of Human Origin (SoHO) Regulation Review Programme launched in 2024 to consider recent changes that the European Union has made to its SoHO Regulation ((EU) 2024/1938) as well as stakeholder proposals for legislation in this area. It is reviewing: patient safety; intra-United Kingdom and UK-EU supply of SoHO; innovation within the sector; and health inequalities.A key principle of the review is to maintain compatible high levels of minimum safety and quality standards for blood, blood components, tissues and cells, human breast milk, intestinal microbiota and blood preparations that are not used for transfusion, to support public health and the movement of SoHO. A targeted consultation, planned to launch by the end of 2025, will give stakeholders the opportunity to share views and highlight key issues and opportunities.

Whether his Department plans to support the domestic (a) collection and (b) processing of (i) blood, (ii) plasma, (iii) cells and (iv) tissues.

NHS Blood and Transplant (NHSBT) is responsible for blood services in England and also manages the NHS Organ Donor Register (ODR), which includes tissue donation for the supply of human tissue grafts for use in surgery. The Department provides Grant in Aid and seed funding to support NHSBT to grow and diversify donor bases, as well as its capacity to process collections.Between 1 April 2024 and 31 March 2025, NHSBT met 99.9% of hospital demand for red cells from domestic collections; the remaining 0.01% of units were imported from other United Kingdom blood services.The Department, NHSBT and NHS England worked together since 2021 to deliver an end-to-end domestic supply chain for plasma-based medicines, enabling UK plasma to be processed into lifesaving medications in specialist facilities in Europe. Since March 2025, this has increased self-sufficiency from 0% to 25% for immunoglobulins and from 0% to 80% for albumin.The Department’s stem cell programme supports diverse recruitment of UK donors onto the UK Stem Cell Register. A global pool of donors is needed to cover the Human Leukocyte Antigen (HLA) diversity of the population so NHSBT works with international stem cell registries to meet patient demand.NHSBT works to encourage people to consider signing the ODR including during the upcoming Organ Donation Week between 22 and 26 September 2025. However, there is no mandate for National Health Service establishments to acquire tissue from NHSBT therefore they can acquire from other sources, such as non-UK tissue banks.

When his Department plans to consult on reforms to the UK’s Substances of Human Origin; and whether that consultation will include proposals on (a) innovation, (b) patient safety and (c) donor protection.

The Substances of Human Origin (SoHO) Regulation Review Programme launched in 2024 to consider recent changes that the European Union has made to its SoHO Regulation ((EU) 2024/1938) as well as stakeholder proposals for legislation in this area. It is reviewing: patient safety; intra-United Kingdom and UK-EU supply of SoHO; innovation within the sector; and health inequalities.A key principle of the review is to maintain compatible high levels of minimum safety and quality standards for blood, blood components, tissues and cells, human breast milk, intestinal microbiota and blood preparations that are not used for transfusion, to support public health and the movement of SoHO. A targeted consultation, planned to launch by the end of 2025, will give stakeholders the opportunity to share views and highlight key issues and opportunities.

With reference to Imkaan’s report entitled Why should our rage be tidy, published in November 2024, whether (a) black and (b) minoritised survivors of domestic abuse are informed of by and for support services by their GP.

Imkaan’s report highlights the distinct and additional challenges faced by black and minoritised victims of domestic abuse and sexual violence. The Government recognises that racial health inequalities are linked to broader socioeconomic factors. Tackling these inequalities is central to building a fairer health system where outcomes are not dictated by race or background. That is why NHS England has introduced a framework for integrated care boards (ICBs) to reduce disparities in outcomes and improve access to treatments.All National Health Service staff, including general practitioners (GPs), are required to complete mandatory safeguarding training which includes how to identify, support and respond to domestic abuse and sexual violence. Safeguarding Leads within local NHS trusts, ICBs and general practices are responsible for ensuring practitioners are offering appropriate professional advice, support, and assurance to prevent harm, including onward referrals to specialist support services. Commissioning of support services for victims of abuse should be tailored to meet the needs and demographics of the local population.

With reference to Imkaan’s report entitled Why Should Our Rage be Tidy, published in November 2024, what steps he is taking to ensure that the NHS is equipped to (a) identify and (b) appropriately respond to signs of domestic and sexual violence.

Imkaan’s report highlights the distinct and additional challenges faced by black and minoritised victims of domestic and sexual violence. All National Health Service staff are required to complete mandatory safeguarding training which includes how to identify and respond to domestic and sexual violence. This training is being revised and is due to be re-launched in early 2026. The training update will strengthen the importance of intersectional considerations, including helping staff to understand the impact of trauma and cultural barriers to discussing abuse.There are a wide range of healthcare services that victims and survivors can access including sexual assault referral centres, which provide medical, practical and emotional support to victims of sexual assault and onward referral to wider support services.National Health Service trusts and integrated care boards have appointed Domestic Abuse and Sexual Violence leads to review their policies, training and support systems for patients and staff. This network of leads is used to help share and promote good practice, identify issues and develop practical solutions to support both patients and staff affected by domestic abuse and sexual violence.